Registry Platform Gastric/Esophageal Cancer (SAPHIR)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Esophageal Cancer
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
SAPHIR is a national, observational, prospective, longitudinal, multicenter cohort study (tumor registry platform) with the purpose to record information on the antineoplastic treatment of metastatic esophageal, gastric or gastroesophageal junction Cancer in Germany. The registry will follow patient...
SAPHIR is a national, observational, prospective, longitudinal, multicenter cohort study (tumor registry platform) with the purpose to record information on the antineoplastic treatment of metastatic esophageal, gastric or gastroesophageal junction Cancer in Germany. The registry will follow patients for up to two years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. Health-related quality of life (HRQoL) will be evaluated for up to two years.
Tracking Information
- NCT #
- NCT04290806
- Collaborators
- Not Provided
- Investigators
- Study Chair: Tobias Dechow, Prof. Ravensburg Study Chair: Albrecht Kretzschmar, Dr. Leipzig Study Chair: Florian Lordick, Prof. Leipzig Study Chair: Sylvie Lorenzen, Prof. München Study Chair: Karin Potthoff, Dr. Freiburg Study Chair: Anke Reinacher-Schick, Prof. Bochum
Get Well Soon